Brief: Lenz Therapeutics Announces Positive Topline Data From Phase 3 Clarity Presbyopia Trials

LENZ Therapeutics

03/04/2024 12:11

April 3 (Reuters) - Lenz Therapeutics Inc  LENZ.O :
    * LENZ THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM
PHASE 3
CLARITY PRESBYOPIA TRIALS
    * LENZ THERAPEUTICS INC: PRIMARY ENDPOINT WAS MET WITH 71%
OF
PARTICIPANTS DOSED WITH LNZ100 ACHIEVING THREE-LINES OR GREATER
IMPROVEMENT AT 3 HOURS
    * LENZ THERAPEUTICS INC: NEW DRUG APPLICATION SUBMISSION
ANTICIPATED IN MID-2024
    * LENZ THERAPEUTICS INC:  PREPARATIONS FOR COMMERCIALIZATION
OF
LNZ100 IN SECOND HALF OF 2025, UPON FDA APPROVAL

Source text for Eikon:  ID:nBw5t06hxa 
Further company coverage:  LENZ.O 

 ((Reuters.Briefs@thomsonreuters.com;))